Claims for Patent: 7,829,503

Summary for Patent: 7,829,503

Title:	Methods of identifying compounds that target tRNA splicing endonuclease and uses of said compounds as anti-fungal agents
Abstract:	The present invention relates to a method for screening and identifying compounds that modulate the activity of a fungal tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit or reduce the activity of a fungal tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for preventing, treating, managing and/or ameliorating a fungal infection or fungal infestation or one or more symptoms thereof.
Inventor(s):	Trotta; Christopher R. (Somerset, NJ)
Assignee:	PTC Therapeutics, Inc. (South Plainfield, NJ)
Application Number:	10/551,304
Patent Claims:	1. A method for identifying a compound that modulates the ability of fungal tRNA splicing endonuclease to produce mature tRNA, the method comprising: (a) contacting a compound or a compound from a library of compounds of compounds with a fungal cell that contains the fungal tRNA splicing endonuclease and expresses a full-length protein encoded by the coding region of a reporter gene of a nucleic acid substrate, wherein the nucleic acid substrate comprises the coding region of a reporter gene and a tRNA intron in a mature domain of a precursor tRNA, and wherein the tRNA intron is contained within the nucleic acid substrate such that the transcribed mRNA from the coding region of the reporter gene is out of frame; and (b) detecting the amount of full-length protein expressed, wherein an alteration in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from the library of compounds or in the presence of a negative control indicates that the compound or the compound from the library of compounds modulates the ability of fungal tRNA splicing endonuclease to produce mature tRNA. 2. The method of claim 1, wherein a decrease in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from the library of compounds or the presence of a negative control indicates that the compound or the compound from the library of compounds reduces the ability of fungal tRNA splicing endonuclease to produce mature tRNA. 3. The method of claim 1, wherein an increase in the amount of the full-length protein expressed in the presence of the compound or the compound from the library of compounds relative to the amount of the full-length protein expressed in the absence of the compound or the compound from the library of compounds or the presence of a negative control indicates that the compound or the compound from the library of compounds increases the ability of fungal tRNA splicing endonuclease to produce mature tRNA. 4. The method of claim 1 or 2, wherein the coding region of the reporter gene encodes at least one or more coding regions of the reporter genes from the group consisting of firefly luciferase, renilla luciferase, click beetle luciferase, green fluorescent protein, yellow fluorescent protein, red fluorescent protein, cyan fluorescent protein, blue fluorescent protein, beta-galactosidase, beta-glucoronidase, beta-lactamase, chloramphenicol acetyltransferase, and alkaline phosphatase. 5. The method of claim 1 or 2, wherein the fungal cell is a yeast cell. 6. The method of claim 5, wherein the yeast cell is a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, or a Hansenula polymorphacell. 7. The method of claim 1 or 2, wherein the method further comprises assessing the specificity of the compound or the compound from the library of compounds for modulating fungal tRNA splicing endonuclease relative to animalia tRNA splicing endonuclease, wherein such assessment comprises contacting the compound or the compound from the library of compounds with an animalia tRNA splicing endonuclease and the substrate, and detecting the amount of substrate cleaved by the animalia tRNA splicing endonuclease, wherein the compound or the compound from the library of compounds is specific for fungal tRNA splicing endonuclease if the amount of substrate cleaved by the animalia tRNA splicing endonuclease in the presence of the compound or the compound from the library of compounds is not altered relative to the amount of substrate cleaved by the animalia tRNA splicing endonuclease in the absence of the compound or the compound from the library of compounds or the presence of a negative control. 8. The method of claim 3, wherein the method further comprises assessing the specificity of the compound or the compound from the library of compounds for modulating fungal tRNA splicing endonuclease relative to animalia tRNA splicing endonuclease, wherein such assessment comprises contacting the compound or the compound from the library of compounds with an animalia tRNA splicing endonuclease and the substrate, and detecting the amount of substrate cleaved by the animalia tRNA splicing endonuclease, wherein the compound or the compound from the library of compounds is specific for fungal tRNA splicing endonuclease if the amount of substrate cleaved by the animalia tRNA splicing endonuclease in the presence of the compound or the compound from the library of compounds is not altered relative to the amount of substrate cleaved by the animalia tRNA splicing endonuclease in the absence of the compound or the compound from the library of compounds or the presence of a negative control. 9. The method of claim 3, wherein the coding region of the reporter gene encodes at least one or more coding regions of the reporter genes from the group consisting of firefly luciferase, renilla luciferase, click beetle luciferase, green fluorescent protein, yellow fluorescent protein, red fluorescent protein, cyan fluorescent protein, blue fluorescent protein, beta-galactosidase, beta-glucoronidase, beta-lactamase, chloramphenicol acetyltransferase, and alkaline phosphatase. 10. The method of claim 3, wherein the fungal cell is a yeast cell. 11. The method of claim 10, wherein the yeast cell is a Saccharomyces cerevisiae cell, a Schizosaccharomyces pombe cell, a Pichia pastoris cell, or a Hansenula polymorpha cell. 12. The method of claim 1, 2 or 3, wherein the tRNA intron is in the coding region of the reporter gene.

Details for Patent 7,829,503

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2023-03-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2023-03-27
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2023-03-27